Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of AnAPN1 Malaria Transmission-Blocking Vaccine in Healthy Adults
NCT05905432Phase 1Completed
- Sponsor
- Centre de Recherches Médicales de Lambaréné
- Start
- Sep 2023
- Primary completion
- Jan 2025
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of AnAPN1 in malaria (3 arms), sponsored by Centre de Recherches Médicales de Lambaréné. Primary endpoint: Adverse events related to the vaccination at Day 14. Started Sep 2023; status: completed.
02
Drugs
AnAPN1
03
Conditions
malaria
Beyond the preview
Go deeper on NCT05905432.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05905432.